Advancing Treatment of Hepatitis Delta Virus in the United States

Non-CME educational program for U.S. HCPs reviewing HDV etiology, epidemiology, disease progression, screening/diagnosis, care-cascade gaps, and a hypothetical patient case, with an overview of bulevirtide as an FDA-approved treatment option for chronic HDV in eligible adults.

“Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.”

Industry Supporter: Gilead Sciences, Inc.